T-DXd
Breast Cancer
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)
Nakayama T, Niikura N, Yamanaka T, et al.
Breast Cancer. 2024;31(6):1167-1175. doi: 10.1007/s12282-024-01614-1. Epub 2024.
T-DXd
Colorectal Cancer
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): Primary results from a multicentre, randomised, phase 2 trial
Raghav K, Siena S, Takashima A, et al.
Lancet Oncol. 2024;25(9):1147-1162. doi: 10.1016/S1470-2045(24)00380-2. Epub 2024.
Valemetostat
Other/Multi
Population pharmacokinetics of total and unbound valemetostat and platelet dynamics in healthy volunteers and patients with non-Hodgkin lymphoma
Fukae M, Baron K, Tachibana M, Mondick J, Shimizu T.
CPT Pharmacometrics Syst Pharmacol. 2024(10):1641-1654. doi: 10.1002/psp4.13201. Epub 2024.
Pexidartinib
Other/Multi
TURALIO® Risk Evaluation and Mitigation Strategy Program (tREMS): 3-year retrospective hepatic safety assessment
Dharmani C, Fofah O, Fallon M, Rajper AW, Wooddell M, Salas M.
Future Oncol. 2024. doi: 10.1080/14796694.2024.2373687. Epub ahead of print.
T-DXd
Breast Cancer
Concurrent use of trastuzumab deruxtecan and radiation therapy in HER2-positive and HER2-low metastatic breast cancer: A single-center experience and review of the literature.
Bouziane J, Loap P, Cao K, et al.
Am J Clin Oncol. 2024. doi: 10.1097/COC.0000000000001135. Epub ahead of print.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
Iwata H, Xu B, Kim S-B, et al.
Cancer Sci. 2024;115(9):3079-3088. doi: 10.1111/cas.16234. Epub 2024 Jul 9.
HER3-DXd
Lung Cancer
Real-world treatment patterns and clinical outcomes among patients with metastatic or unresectable EGFR-mutated non-small cell lung cancer previously treated with osimertinib and platinum-based chemotherapy
Patel J, Meng J, Le H, et al.
Adv Ther. 2024;41(8):3299-3315. doi: 10.1007/s12325-024-02936-4. Epub 2024.
Valemetostat
Lung Cancer
A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer
Choudhury NJ, Lai WV, Makhnin A, et al.
Clin Cancer Res. 2024;30(17):3697-3703. doi: 10.1158/1078-0432.CCR-23-3383.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: Subgroup analysis of the DESTINY-Breast04 study
Yamashita T, Sohn JH, Tokunaga E, et al.
Breast Cancer. 2024;31(5):858-868. doi: 10.1007/s12282-024-01600-7.
T-DXd
Breast Cancer
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: Long-term survival analysis of the DESTINY-Breast03 trial
Cortés J, Hurvitz SA, Im S-A, et al.
Nat Med. 2024;30(8):2208-2215. doi: 10.1038/s41591-024-03021-7.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26